Adj Abemaciclib HR+/HER2- EBC

CE / CME

Risk Assessment and Ki-67 Testing in HR-Positive/HER2-Negative EBC for Adjuvant Abemaciclib

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Nurses: 0.50 Nursing contact hour

Released: May 12, 2022

Expiration: May 11, 2023

Yara Abdou
Yara Abdou, MD

Activity

Progress
1
Course Completed

In this module, Yara Abdou, MD, discusses risk assessment and the role of Ki-67 testing for adjuvant therapy with the CDK4/6 inhibitor abemaciclib for patients with hormone receptor–positive (HR+), HER2-negative (HER2-), node-positive, high-risk, early breast cancer (EBC).

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with breast cancer do you provide care for in a typical month?

You are treating a 46-year-old woman diagnosed with left breast T3N3M0 invasive ductal carcinoma, estrogen receptor positive, progesterone receptor positive, and HER2 negative. She has completed neoadjuvant chemotherapy, followed by surgery and adjuvant radiation therapy. She is now receiving adjuvant abemaciclib with letrozole. She presents to clinic complaining of having 4-6 watery bowel movements daily despite taking loperamide every 8 hours.

How would you manage this patient’s diarrhea?